FDA grants givinostat Rare Paediatric Disease Designation for Duchenne Muscular Dystrophy

Givinostat is a histone deacetylase (HDAC) inhibitor. In a Phase II study in boys with Duchenne Muscular Dystrophy, it was associated with slower disease progression. Patient enrolment into the EPIDYS Phase III trial has been completed (n=179), with results expected in June 2022.

Source:

Biospace Inc.